Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Levine

Reproductive Endocrinology Fishkill, NY Medical Doctor

NPI 1679584312 CMS profile 76233

400 Westage Business Center Dr., Suite 109, Fishkill, NY 12524

Open in the dashboard

General payments

$5,002

281 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Levine of Fishkill, NY is reported in the CMS Open Payments database as having received $5,002 across 281 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $297 19
2024 General $292 16
2023 General $565 16
2022 General $592 38
2021 General $804 52
2020 General $475 46
2019 General $1,977 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Levine
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Daniel Levine were reported at $297. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Daniel Levine Reproductive Endocrinology median Middle half National median
2019 $1,977 $196 $77–$425 $163
2020 $475 $81 $35–$182 $114
2021 $804 $102 $43–$247 $132
2022 $592 $139 $62–$303 $149
2023 $565 $141 $65–$285 $160
2024 $292 $144 $65–$302 $164
2025 $297 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ferring Pharmaceuticals Inc. $2,863 208 payments
  2. AbbVie, Inc. $924 29 payments
  3. Exeltis, USA Inc. $243 17 payments
  4. Covidien LP $189 2 payments
  5. Novo Nordisk Inc $180 4 payments
  6. CooperSurgical, Inc. $160 3 payments
  7. AMAG Pharmaceuticals, Inc. $124 1 payment
  8. Alfasigma USA, Inc. $108 6 payments
  9. EMD Serono, Inc. $70 3 payments
  10. Merck Sharp & Dohme Corporation $36 2 payments
  11. Other $103 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,987 279 payments
  2. Education $15 2 payments
Products named General payments · program years 2019–2025
  1. MENOPUR Reproductive Health $2,312 175 payments
  2. Orilissa Endocrinology $598 15 payments
  3. MENOPUR Reproductive Health $509 32 payments
  4. ORILISSA Womens Health $225 11 payments
  5. TruClear $189 2 payments
  6. Wegovy $180 4 payments
  7. ORIAHNN $156 8 payments
  8. INTRAROSA $124 1 payment
  9. Vitafol Ultra $120 14 payments
  10. STRIPPER $118 2 payments
  11. Other $410 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

281 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record